Search Results

You are looking at 71 - 80 of 420 items for :

  • "single agent" x
Clear All
Full access

Joyce Liu and Ursula Matulonis

. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol 2001 ; 19 : 3312 – 3322 . 15. Cantu MG Buda A Parma G . Randomized controlled trial of single-agent

Full access

Ajeet Gajra, Alissa S. Marr and Apar Kishor Ganti

stage IV NSCLC and a PS 2, including issues such as treatment with single-agent versus combination and choice of specific agents, such as biologics. Current ASCO guidelines for chemotherapy in stage IV NSCLC state, “Available data support use of single-agent

Full access

David M. O’Malley

-containing chemotherapy regimens, single-agent maintenance therapy with bevacizumab is a category 2A recommended option. “Among gynecologic cancers, ovarian cancer is the number 1 cancer killer. The median survival has improved from 2 to 5 years with newer approaches. Now

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar and Dorothy A. Shead

of NCCN®. Bortezomib has been shown to have high levels of activity in the management of WM as a single agent, 8 in combination with rituximab, 9 or in combination with rituximab and dexamethasone. 10 , 11 In a phase II study, bortezomib

Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour and David J. Sher

; fluorouracil/leucovorin/irinotecan/oxaliplatin), have shown a survival benefit with multiagent versus single-agent chemotherapy. According to current NCCN Guidelines, gemcitabine + capecitabine, mFOLFIRINOX, gemcitabine monotherapy, and 5-FU/leucovorin are all

Full access

Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet and Katherine M. Pisters

-trial first-line drug therapy are shown in Figure 1 . Platinum-based doublets (n = 676; 60%) and platinum-based doublets combined with a targeted therapy agent (n = 214; 19%) constituted the most common therapy strategies for this group. Single-agent targeted

Full access

Rona Yaeger and Leonard Saltz

, however. Kopetz et al 8 treated 21 patients with V600E BRAF mutations with single-agent vemurafenib; only one patient experienced an objective response. Preclinical studies are underway to investigate the reasons why these agents lack activity in

Full access

-in (part A), 6 patients will be treated with the combination of enzalutamide and standard intravenous carboplatin and paclitaxel. Patients on the phase II portion of study (part B) will undergo induction treatment with single-agent enzalutamide at 160 mg

Full access

processes involved in disease response and development of resistance to antiandrogen therapy. After completion of study treatment, patients are followed for up to 5 years. Primary Objective: Perform a preliminary assessment of the efficacy of single-agent

Full access

. In addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in patients with previously treated angiosarcomas in the phase II setting. Bevacizumab has